Document is current
Any future updates will be listed below
-
Authors
Chen, Jiannan
Zhao, Lianfeng
Li, Wenying
Wang, Shuai
Li, Jiayi
Lv, Zhongyuan
Zhao, Yaoyao
Liang, Junqing
Hu, Zhigang
Pan, Feiyan
He, Lingfeng
Gu, Lili
Guo, Zhigang
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05372692 at ClinicalTrials.govDocuments that mention this clinical trial
Glutamine-driven metabolic reprogramming promotes CAR-T cell function through mTOR-SREBP2 mediated HMGCS1 upregulation in ovarian cancer
https://doi.org/10.1186/s12967-025-06853-0
Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model
https://doi.org/10.1136/jitc-2022-006509
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82373183)
Priority Academic Program Development of Jiangsu Higher Education Institutions
- License Information
-
More Information
Article History
Received: 4 May 2025
Accepted: 9 July 2025
First Online: 17 July 2025
Declarations
:
: This study was approved by the Institutional Review Board and the Clinical Research Ethics Committee of the First Affiliated Hospital, College of Medicine, Zhejiang University and the Animal Experiment Ethics Committee of Nanjing Normal University (IACUC-2024234) for animal studies. All participants provided written informed consent before enrollment in the clinical trial.
: All authors have consented to the publication of the research findings.
: The authors report there are no competing interests to declare.
